EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access

Impact of daily adaptive head and neck radiotherapy on toxicity and quality of life: results of the DARTBOARD phase II randomized trial

David J Sher iD, Vladimir Avkshtol iD, Mu-Han Lin iD, Jing Wang iD, Liyuan Chen iD, Chien-Yi Liao iD, Randall Hughes, Sean Domal iD, Chul Ahn iD, Dominic H Moon iD

JNCI: Journal of the National Cancer Institute · 01.12.2025 · 117 (12) · 2488-2494

DOI: 10.1093/jnci/djaf232 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 20.08.2025. Verfasst von David J Sher und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States. Hauptthemen laut MEDLINE: Quality of Life, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Radiotherapy, Image-Guided. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Varian Medical Systems.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The utility of adaptive radiotherapy (ART) for head and neck squamous cell carcinoma (HNSCC) remains poorly defined. Daily ART (DART) promises both anatomic adaptation and planning target volume (PTV) reduction. In this prospective trial using cone-beam computed tomography-based ART, patients with HNSCC undergoing definitive radiotherapy (RT) or chemoradiotherapy (CRT) were randomly assigned to DART with reduced PTV margins or no ART with standard margins (image-guided RT [IGRT]).

Methods

Eligibility criteria included a diagnosis of oropharynx, larynx, or hypopharynx HNSCC receiving definitive radiotherapy. All individuals received involved nodal radiotherapy per previous institutional study. The PTV margins were 1 mm (2 mm craniocaudal) vs 5 mm in the DART and IGRT arms, respectively. The primary endpoint was patient-reported xerostomia at 1 year, assessed with the Xerostomia Questionnaire (XQ).

Results

Fifty patients were enrolled (26 IGRT, 24 DART) between March 2022 and June 2023. The cohort consisted of 38 oropharynx and 12 larynx/hypopharynx patients. The mean ipsilateral parotid gland, ipsilateral and contralateral submandibular gland doses were significantly lower with DART. There was significantly less acute dermatitis in the DART arm (Grade 0/1/2 0%/69%/31% vs 17%/75%/8% DART, P = .01) but no significant difference in any patient-reported outcome at 1 year. The adjusted difference in XQ score at 1 year was 10.0 (95% CI = −4.7 to 24.7, P = .58).

Conclusion

Online DART for HNSCC is oncologically sound and improved acute toxicity profiles, but it did not reduce patient-reported xerostomia, the primary endpoint. Additional evidence is needed to understand the potential benefits and limitations of this paradigm, including its cost-effectiveness. Trial registration clinicaltrials.gov identifier, NCT04883281

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckRadiotherapy, Image-GuidedHumansMaleFemaleMiddle AgedAgedXerostomiaProspective StudiesCone-Beam Computed TomographyRadiotherapy Planning, Computer-AssistedChemoradiotherapyAdult

Autor:innen und Institutionen

  • Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
  • Medical Artificial Intelligence and Automation (MAIA) Laboratory, Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
  • Department of Medical Oncology, UT Southwestern Medical Center, Dallas, TX, United States.
  • Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX, United States.

ORCID-Profile: David J Sher, Vladimir Avkshtol, Mu-Han Lin, Jing Wang, Liyuan Chen, Chien-Yi Liao, Sean Domal, Chul Ahn, Dominic H Moon

Förderung

  • NCI NIH HHS
  • Varian Medical Systems

Zitieren

APA

Sher, D. J., Avkshtol, V., Lin, M. H., Wang, J., Chen, L., Liao, C. Y., Hughes, R., Domal, S., Ahn, C., & Moon, D. H. (2025). Impact of daily adaptive head and neck radiotherapy on toxicity and quality of life: results of the DARTBOARD phase II randomized trial. JNCI: Journal of the National Cancer Institute, 117(12), 2488-2494. https://doi.org/10.1093/jnci/djaf232

Vancouver

Sher DJ, Avkshtol V, Lin MH, Wang J, Chen L, Liao CY, et al. Impact of daily adaptive head and neck radiotherapy on toxicity and quality of life: results of the DARTBOARD phase II randomized trial. JNCI: Journal of the National Cancer Institute. 2025;117(12):2488-2494. doi:10.1093/jnci/djaf232

BibTeX
@article{Sher2025,
  author = {Sher, David J and Avkshtol, Vladimir and Lin, Mu-Han and Wang, Jing and Chen, Liyuan and Liao, Chien-Yi and Hughes, Randall and Domal, Sean and Ahn, Chul and Moon, Dominic H},
  title = {Impact of daily adaptive head and neck radiotherapy on toxicity and quality of life: results of the DARTBOARD phase II randomized trial},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  volume = {117},
  number = {12},
  pages = {2488--2494},
  doi = {10.1093/jnci/djaf232}
}
Kostenlos starten →